Oncology Drugs

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

A new report shows hospitals in a federal drug discount program provide less charity care than others, fueling calls for urgent federal reforms.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

A $182,500 seizure in Quebec is just the tip of the iceberg, revealing a nationwide struggle against high-tech smuggling, drones, and prison violence.

A revolutionary single-dose, over-the-counter cold sore tablet launches in Europe, promising new convenience for millions and shaking up the self-care market.

Caliway Biopharma advances its fat-loss drug, promising objective, MRI-verified results in a market hungry for safer, more reliable aesthetic options.

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

New data shows Moleculin Biotech's Annamycin avoids heart toxicity, a breakthrough that could transform treatment for leukemia and sarcoma patients.

Teva's new once-monthly olanzapine injection could revolutionize schizophrenia care in Europe, offering hope for better treatment adherence and patient outcomes.

A new data partnership between Ontada and Florida Cancer Specialists aims to transform cancer research by leveraging real-world evidence from community clinics.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

With a new CCO and advanced T-Body™ platform, Invenra is shifting from R&D to aggressive commercialization. Can it dominate the multispecific antibody market?

The cancer center's prestigious FACT accreditation for bone marrow transplants brings world-class blood cancer treatment closer to home for patients in Georgia.